APOS Therapy for Osteoarthritis of the Knee: a Randomized Controlled Trial BIOTOK
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Feb 9, 2015
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
Background
Osteoarthritis (OA) is the most common arthritic condition and is one of the leading causes of disability in adults in Switzerland and worldwide (CDC 2009, WHO 2004). With the steady escalation of world life expectancy and constant decline in world birth rates, the incidence and prevalence of OA are expected to rise continuously worldwide throughout the years to come (Badley 1998). In Switzerland, OA is associated with decreased quality of life and frequent use of the health care system (Rosemann 2008).
Currently, no treatment can stop or reverse the progressive joint degenerat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men or non-pregnant women
- • Aged \>= 40
- • Outpatient setting
- • ACR clinical criteria for OA of the knee
- • Radiologically confirmed symptomatic uni- or bilateral OA of the knee for at least 6 months
- • Radiological criteria: X-rays showing tibiofemoral knee osteoarthritis defined as at least Kellgren and Lawrence Grade 2
- • At least moderate pain on the WOMAC pain scale (\>3 on a standardized scale range from a minimum of 0 to a maximum of 10)
- • Must understand German
- • Informed Consent documented by participant signature
- • Exclusion Criteria
- • Pregnant women
- • Aged \< 40
- • History of an inflammatory rheumatic disease
- • Non-knee musculoskeletal pain as or more severe than the knee pain
- • Glucocorticoid injections in the knees in the previous three month
- • Previous osteotomy
- • Unilateral hemiprosthesis
- • Unilateral total joint replacement
- • Being treated for cancer
- • Participation in another clinical trial
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berne, , Switzerland
Patients applied
Trial Officials
Stephan Reichenbach, PD Dr. med.
Principal Investigator
Institute of Social and Preventive Medicine (ISPM), University of Bern
Peter Jüni, Prof.
Study Director
Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Canada
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials